- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05797285
Evaluating The Efficacy Of A Keratin Graft In Treating Non-Healing Diabetic Foot Ulcers
A Randomized Clinical Pilot Evaluating The Efficacy For Two Application Regimens Of A Unique Keratin Based Graft In The Treatment Of Non-Healing Diabetic Foot Ulcers
The goal of this clinical pilot is to collect patient outcome data on a commercially available, keratin-based skin substitute matrix: ProgenaMatrix®. In this trial, two groups of patients with diabetic foot ulcers (DFUs) will be randomized to receive treatment with ProgenaMatrix applied either weekly or bi-weekly to the target wound. Researchers will compare how weekly or bi-weekly application of ProgenaMatrix affects the healing of DFUs.
The primary questions to be answered are:
- How many patients achieve wound closure in 12 weeks with ProgenaMatrix treatment? And
- What is the change in wound area during the trial in each group?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
ProgenaMatrix® is a human keratin graft that is 510K approved for application on diabetic foot wounds and has been shown in case studies and clinical practice to assist in wound healing . Additionally, a study published by Tang and Kirsner showed that keratin stimulates human keratinocyte migration and types IV and VII collagen expression. Therefore, based on this early promising data, a larger pilot is necessary to further validate these results and identify the likelihood of wound healing with weekly versus bi-weekly application. For consistency, one type of wound will be studied in this trial and DFU's have been chosen as they are some of the most common wounds seen in the wound clinics.
The purpose of this clinical evaluation is to collect patient outcome data on a commercially available 510K FDA cleared synthetic, absorbable skin substitute matrix. The commercially available product is ProgenaMatrix® Advanced Wound Graft and consists of Human Keratin Matrix. In this trial, two groups of subjects with diabetic foot ulcers (DFUs), will receive standard of care (SOC) treatment for their condition. Half of the patients will be randomized to a 510K FDA cleared ProgenaMatrix® applied weekly and the other half will be randomized to a 510K FDA cleared ProgenaMatrix® applied bi-weekly (i.e., once every two weeks).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33143
- Doctors Research Network
-
-
Maryland
-
Frederick, Maryland, United States, 21703
- Foot and Ankle Specialists of the Mid-Atlantic (FASMA)
-
-
Virginia
-
Salem, Virginia, United States, 24153
- Foot and Ankle Specialists of the Mid-Atlantic (FASMA)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of type 1 or 2 diabetes mellitus
- Target diabetic foot ulcer with a minimum surface area of 1.0 cm^2 and a maximum surface area of 20.0 cm^2 measured post-debridement with photographic planimetry.
- Target ulcer must have been present for a minimum of 4 weeks and maximum of 52 weeks of standard of care prior to initial screening
- Target ulcer must be located on the foot with at least 50% of its area below the malleolus
- Target ulcer must be full thickness on the foot or ankle that does not probe to bone
- Adequate circulation in the affected foot documented within 3 months of initial screening visit, as determined by one of the following: transcutaneous oximetry measurement (TCOM) greater or equal to 30 mmHg, ankle-brachial index (ABI) between 0.7 and 1.3, biphasic pulse volume recording (PVR), toe-brachial index (TBI) greater than 0.6, or arterial Doppler ultrasound evaluating for biphasic dorsalis pedis and posterior tibial vessels at the ankle level
- If subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer
- Target ulcers on the plantar aspect of the foot must be offloaded for at least 14 days prior to randomization
- Subject must consent to using the prescribed off-loading method for the duration of the study
- Subject must agree to attend weekly study visits required by the protocol
- Subject must be willing and able to participate in the informed consent process
Exclusion Criteria:
- Subjects known to have a life expectancy of < 6 months
- Infection of the target ulcer or cellulitis in the surrounding skin
- Presence of osteomyelitis or exposed bone, or wounds that probe to bone or joint capsule on investigator's exam or radiographic evidence
- Infection in the target ulcer requiring systemic antibiotic therapy
- Subjects receiving immunosuppressants (including systemic corticosteroids > 10 mg Prednisone per day or equivalent) or cytotoxic chemotherapy
- Topical application of steroids to the ulcer surface within one month of initial screening
- Subjects with previous partial amputation on the affected foot that impedes proper offloading of the target ulcer
- Subjects with a glycated hemoglobin (HbA1c) greater than or equal to 13% taken at or within 3 months of the initial screening visit
- Subjects with a serum creatinine level ≥ 3.0mg/dL within 6 months of randomization
- Surface area of the target ulcer reduces in size by more than 30% in the two weeks between the initial screening and randomization during which they are subject to standard of care
- Subjects with acute or inactive Charcot foot that impedes proper offloading of the target ulcer
- Women who are pregnant or considering becoming pregnant within the next 6 months
- Subjects with end stage renal disease requiring dialysis
- Subjects who participated in a clinical trial involving treatment with an investigational product within the previous 30 days
- Subjects who, in the opinion of the investigator, have a medical or psychological condition that may interfere with study assessments
- Subjects treated with hyperbaric oxygen therapy or a cellular and/or tissue product (CTP) in the 30 days prior to the initial screening visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Weekly Human Keratin Graft Application
Patients randomized into this arm will receive standard of care (offloading, debridement, and three-layer outer dressing) with the test material, the human keratin graft, reapplied weekly to the target wound.
|
The intervention to be applied is an advanced wound care matrix composed of human keratin to be applied at two different treatment frequencies.
Other Names:
|
Experimental: Bi-Weekly Human Keratin Graft Application
Patients randomized into this arm will receive standard of care (offloading, debridement, and three-layer outer dressing) with the test material, the human keratin graft, reapplied every other week to the target wound.
|
The intervention to be applied is an advanced wound care matrix composed of human keratin to be applied at two different treatment frequencies.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wound Closure
Time Frame: 12 weeks
|
The proportion of subjects that achieve complete closure of the target wound with each treatment.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Wound Closure
Time Frame: From date of randomization until date of documented wound closure, assessed up to 12 weeks
|
The time required for target ulcers to achieve complete closure with each treatment.
|
From date of randomization until date of documented wound closure, assessed up to 12 weeks
|
Wound Area Change
Time Frame: From date of randomization until date of documented wound closure or study conclusion, whichever comes first, assessed up to 12 weeks
|
The change in target wound area between treatment visits.
|
From date of randomization until date of documented wound closure or study conclusion, whichever comes first, assessed up to 12 weeks
|
Change in Peripheral Neuropathy
Time Frame: From date of randomization until date of documented wound closure or study conclusion, whichever comes first, assessed up to 12 weeks
|
Changes in peripheral neuropathy of the foot with the target ulcer between treatment visits, assessed by the standard 10-point Semmes-Weinstein monofilament exam.
|
From date of randomization until date of documented wound closure or study conclusion, whichever comes first, assessed up to 12 weeks
|
Change in Wound Pain
Time Frame: From date of randomization until date of documented wound closure or study conclusion, whichever comes first, assessed up to 12 weeks
|
Changes in pain in the target ulcer assessed by the numerical pain rating scale from 0 (no pain) to 10 (worst pain possible).
|
From date of randomization until date of documented wound closure or study conclusion, whichever comes first, assessed up to 12 weeks
|
Change in Quality of Life
Time Frame: From date of first screening until date of documented wound closure or study conclusion, whichever comes first, assessed up to 15 weeks
|
Changes in patient quality of life relating to their wound using the wound quality of life assessment with 17 questions answered on a scale of 0 ("not at all") to 4 ("very much").
|
From date of first screening until date of documented wound closure or study conclusion, whichever comes first, assessed up to 15 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of Cellulitis and Infection
Time Frame: 12 weeks
|
Difference in number of participants presenting with cellulitis and/or infection in or around the target ulcer between treatment groups.
|
12 weeks
|
Number of Adverse Events Observed
Time Frame: 15 weeks
|
The number and type of adverse events observed during the study.
|
15 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: David G Armstrong, DPM,MD,PhD, University of Southern California
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRG-PM-DFU-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcer
-
University of MinnesotaRecruitingDiabetes Mellitus | Foot Ulcer | Ulcer | Diabetic Foot Ulcer | Foot Ulcer, Diabetic | Ulcer Foot | Ulcer, Leg | Ankle UlcerUnited States
-
Community Pharmacology Services LtdKeneric HealthcareNot yet recruitingDiabetic Foot Ulcer | Diabetic Foot Ulcer Neuropathic | Diabetic Foot Ulcer Ischemic
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly
-
Corporacion Parc TauliCompletedDiabetic Foot Ulcer | Diabetic Foot Ulcer NeuropathicPakistan
-
Johns Hopkins UniversityWithdrawnDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Mixed | Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)
-
Baylor College of MedicineLifeNet HealthCompletedDiabetic Foot Ulcer | Deep Diabetic Foot UlcerUnited States
-
Exciton Technologies Inc.CompletedDiabetic Foot Ulcer | Diabetic Foot Infection | Non-healing Diabetic Foot UlcerCanada
-
ETS Wound Care, LLCProfessional Education and Research InstituteCompletedDiabetic Foot | Diabetic Foot Ulcer | Ulcer FootUnited States
-
National and Kapodistrian University of AthensTerminatedDiabetic Foot | Chronic Diabetic Foot Ulcer of Right Foot | Neuropathic Foot Ulcer | Chronic Diabetic Ulcer of Left Foot (Diagnosis)Greece
-
University of the PunjabHigher Education Commission (Pakistan); Centre of Excellence in Molecular Biology... and other collaboratorsRecruitingDiabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetes Complications | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | Chronic Diabetic Ulcer of Left Foot | Chronic Diabetic Foot...Pakistan
Clinical Trials on human keratin graft
-
ProgenaCare Global, LLCActive, not recruiting
-
Humacyte, Inc.FGK Clinical Research GmbHActive, not recruitingKidney Failure, Chronic | End-stage Renal DiseasePoland
-
University of Auckland, New ZealandHealth Research Council, New ZealandCompleted
-
Medical University of ViennaSurgebright GmbhRecruitingOsteochondral DefectAustria
-
Sohag UniversityRecruiting
-
Orthopedic Foot and Ankle Center, OhioTerminatedTendon TearsUnited States
-
Vidfarma Indústria de Medicamentos Ltda.UnknownHemorrhoids | Chronic Venous InsufficiencyBrazil
-
Vascudyne, Inc.CompletedEnd Stage Renal DiseaseParaguay
-
ProofPilotNoho HealthCompletedSkin Aging | Skin Laxity | Hair Loss | Cosmetic Acne | Nails; SoftUnited States
-
Klinikum Wels-GrieskirchenSurgebright GmbhUnknownHallux ValgusAustria